Opthea Completes Enrollment in First Trial of Sozinibercept
Filed with ASX · · 4 pages · English
Story so far
Earlier from Opthea
- Opthea to Receive US$35M Commitment and Additional US$50M
- Opthea receives A$8.8 million R&D Tax Incentive
- 2023 AGM Chairmans Address
- Opthea Appoints U.S. Based Leadership
- Opthea to Participate at the 2023 Euretina Congress
Later from Opthea
- Opthea Reports Half-Year Results and Business Update
- Half Yearly Report and Accounts
- Opthea Corporate Presentation - March 2024
- Opthea Key Opinion Leader Even on Sozinibercept
- Opthea Corporate Presentation - April 2024
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea